Shares of CLEMENTIA PHARM (NASDAQ:CMTA) have earned an average broker rating score of 1.13 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and three have given a strong buy recommendation to the company.

Brokers have set a 1-year consensus target price of $27.00 for the company, according to Zacks. Zacks has also given CLEMENTIA PHARM an industry rank of 154 out of 265 based on the ratings given to its competitors.

CMTA has been the subject of a number of research analyst reports. Morgan Stanley initiated coverage on shares of CLEMENTIA PHARM in a report on Monday, August 28th. They issued an “overweight” rating and a $27.00 target price for the company. Wedbush initiated coverage on shares of CLEMENTIA PHARM in a report on Monday, August 28th. They issued an “outperform” rating and a $26.00 target price for the company. Leerink Swann initiated coverage on shares of CLEMENTIA PHARM in a report on Monday, August 28th. They issued an “outperform” rating and a $23.00 target price for the company. Finally, BTIG Research initiated coverage on shares of CLEMENTIA PHARM in a report on Thursday, August 31st. They issued a “buy” rating and a $32.00 target price for the company.

CLEMENTIA PHARM (NASDAQ CMTA) traded down 0.37% during midday trading on Thursday, reaching $15.99. The company’s stock had a trading volume of 141,206 shares. CLEMENTIA PHARM has a 52 week low of $9.95 and a 52 week high of $17.33. The company’s 50-day moving average is $16.14 and its 200 day moving average is $15.46. The firm’s market capitalization is $488.13 million.

TRADEMARK VIOLATION WARNING: “Zacks: CLEMENTIA PHARM (CMTA) Given Consensus Recommendation of “Strong Buy” by Brokerages” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/10/zacks-clementia-pharm-cmta-given-consensus-recommendation-of-strong-buy-by-brokerages.html.

CLEMENTIA PHARM Company Profile

Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.

Get a free copy of the Zacks research report on CLEMENTIA PHARM (CMTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for CLEMENTIA PHARM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CLEMENTIA PHARM and related stocks with our FREE daily email newsletter.